Cytos’ CYT003 Fails to Achieve Clinical Trial Endpoint

Cytos Biotechnology yesterday announced that their Phase IIb clinical study of CYT003 failed to meet its primary or secondary endpoints. The clinical trial tested patients with moderate to severe allergic asthma,  and showed that the immune modulator did not achieve a statistically significant reduction of the Asthma Control Questionnaire (ACQ) score at week 12 in

Continue Reading